Literature DB >> 15039538

Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner.

Takashi Taguchi1,2, Motoko Nagano-Fujii2, Masato Akutsu2, Hiroyasu Kadoya2, Shinji Ohgimoto2, Satoshi Ishido2, Hak Hotta2.   

Abstract

The non-structural protein 5A (NS5A) of hepatitis C virus (HCV) has been implicated in inhibition of antiviral activity of IFN. While previous studies have suggested an interaction between NS5A and the double-stranded RNA-dependent protein kinase (PKR), the possibility still remains that interaction with another molecule(s) is involved in the NS5A-mediated inhibition of IFN. In the present study, we investigated a possible interaction between NS5A and 2',5'-oligoadenylate synthetase (2-5AS), another key molecule in antiviral activity. We observed that NS5A physically interacted with 2-5AS in cultured cells, with an N-terminal portion of NS5A [aa 1-148; NS5A(1-148)] and two separate portions of 2-5AS (aa 52-104 and 184-275) being involved in the interaction. Single point mutations at residue 37 of NS5A affected the degree of the interaction with 2-5AS, with a Phe-to-Leu mutation (F37L) augmenting and a Phe-to-Asn mutation (F37N) diminishing it. Virus rescue assay revealed that the full-length NS5A (NS5A-F) and NS5A(1-148), the latter of which contains neither the IFN sensitivity-determining region (ISDR) nor the PKR-binding domain, significantly counteracted the antiviral activity of IFN. Introduction of a F37N mutation into NS5A(1-148) impaired the otherwise more significant IFN-inhibitory activity of NS5A(1-148). It was also found that the F37N mutation was highly disadvantageous for the replication of an HCV RNA replicon. Taken together, our results suggest the possibility that NS5A interacts with 2-5AS and inhibits the antiviral activity of IFN in an ISDR-independent manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039538     DOI: 10.1099/vir.0.19513-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  38 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population.

Authors:  Xiao-Ming Zhou; Paul Ks Chan; John S Tam
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

Review 3.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.

Authors:  Qi Zhang; Rui Gong; Jing Qu; Yijing Zhou; Weiyong Liu; Mingzhou Chen; Yingle Liu; Ying Zhu; Jianguo Wu
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

5.  RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP.

Authors:  Krishnamurthy Malathi; Takeshi Saito; Nannette Crochet; David J Barton; Michael Gale; Robert H Silverman
Journal:  RNA       Date:  2010-09-10       Impact factor: 4.942

6.  Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.

Authors:  Julie K Pfeiffer; Karla Kirkegaard
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression.

Authors:  Meleri Jones; Andrew Davidson; Linda Hibbert; Petra Gruenwald; Joerg Schlaak; Simon Ball; Graham R Foster; Michael Jacobs
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 8.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 9.  Intracellular innate immune cascades and interferon defenses that control hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

10.  TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

Authors:  D G Cordek; J T Bechtel; A T Maynard; W M Kazmierski; C E Cameron
Journal:  Drugs Future       Date:  2011-09       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.